Project description
Innovative blood test for colorectal cancer screening
Spain-based Universal Diagnostics (UDX) is a biomedical company with a focus on the early detection of cancer. To that end, they are working on a low-cost and efficient method for the detection of early metabolic markers in the blood for different types of cancer using analysis based on mass spectrometry. If diagnosed early, colorectal cancer (CRC) is a preventable disease. UDX has developed an accurate, non-invasive and inexpensive blood-based screening test to detect CRC and precancerous adenomas, enabling prevention and early treatment. The metabolomics platform developed for CRC can be easily modified and applied in the detection of other types of cancer. The EU-funded ColonScan project plans to perform, technical and financial feasibility studies for the commercialisation of the CRC screening method.
Objective
Universal Diagnostics (UDX) is a biomedicine start-up focused on early detection of cancer using leading-edge technologies. Our mission is to make cancer a curable disease by detecting it early through an accurate, simple to use, and cost-effective diagnostic kit.
During the last 5 years, UDX has been developing a mass spectrometry (MS) based metabolic analysis that allows very cost-effective and accurate detection of metabolic markers in blood, for early detection of different types of cancer.
The first product of the company (the one this proposal is all about) is ColonScan: A simple, noninvasive, accurate (AUC 92%) and inexpensive, blood-based screening test to detect colorectal cancer (CRC) and adenomas (precancerous stages), allowing early detection and cancer prevention.
ColonScan will be highly accurate, easily scalable worldwide, simple to use, non-invasive and inexpensive; ColonScan presents all characteristics and requirements to be adopted as CRC screening program for average risk population since, our technology can be included routinely in normal blood tests at annual or biannual medical check-ups. Moreover, the metabolomics platform developed in ColonScan project can be applied and upscaled to other types of cancer with no cost increase.
CRC is the third most commonly diagnosed and leading cause of cancer death in the world, despite CRC is considered a completely preventable disease. All CRC guidelines recommends regularly (annual or biannual) screening of average risk population (50-85 years old).
This represents a huge market opportunity, which according to our conservative estimations means a target population of 380 Million people and 12 Billion market opportunity.
The ultimate objective of ColonScan Phase 1 project is to assess the feasibility of our business innovation project, under a commercial, technical and financial point of view to minimize any potential risk that might endanger our business plan.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicineoncologycolorectal cancer
- natural scienceschemical sciencesanalytical chemistrymass spectrometry
- engineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
41012 SEVILLA
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.